Biotech Values

[DewDiligence]

MYOV bags European partner for Orgovyx:

https://www.globenewswire.com/news-release/2022/05/09/2438369/0/en/Myovant-Sciences-and-Accord-Healthcare-Ltd-Enter-into-Exclusive-License-Agreement-to-Commercialize-ORGOVYX-for-Advanced-Hormone-Sensitive-Prostate-Cancer-in-Europe.html

Myovant Sciences and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey…

…Under the terms of the agreement, Myovant will receive an upfront payment of $50 million and is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million. In addition, Myovant is eligible to receive tiered royalties from the high-teens to mid-twenties on net sales.